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Purpose: Alzheimer’s disease (AD) results in memory impairment and neuronal 
cell death in the brain. Previous studies demonstrated that intracerebroventricular 
administration of streptozotocin (STZ) induces pathological and behavioral altera-
tions similar to those observed in AD. Agmatine (Agm) has been shown to exert 
neuroprotective effects in central nervous system disorders. In this study, we inves-
tigated whether Agm treatment could attenuate apoptosis and improve cognitive 
decline in a STZ-induced Alzheimer rat model. Materials and Methods: We 
studied the effect of Agm on AD pathology using a STZ-induced Alzheimer rat 
model. For each experiment, rats were given anesthesia (chloral hydrate 300 mg/
kg, ip), followed by a single injection of STZ (1.5 mg/kg) bilaterally into each lat-
eral ventricle (5 μL/ventricle). Rats were injected with Agm (100 mg/kg) daily up 
to two weeks from the surgery day. Results: Agm suppressed the accumulation of 
amyloid beta and enhanced insulin signal transduction in STZ-induced Alzheimer 
rats [experimetal control (EC) group]. Upon evaluation of cognitive function by 
Morris water maze testing, significant improvement of learning and memory dys-
function in the STZ-Agm group was observed compared with the EC group. West-
ern blot results revealed significant attenuation of the protein expressions of 
cleaved caspase-3 and Bax, as well as increases in the protein expressions of Bcl2, 
PI3K, Nrf2, and γ-glutamyl cysteine synthetase, in the STZ-Agm group. Conclu-
sion: Our results showed that Agm is involved in the activation of antioxidant sig-
naling pathways and activation of insulin signal transduction. Accordingly, Agm 
may be a promising therapeutic agent for improving cognitive decline and attenu-
ating apoptosis in AD.
Key Words:   Agmatine, streptozotocin, Alzheimer’s disease, cognitive dysfunc-
tion, apoptosis, insulin signal transduction
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia and is a neurode-
generative disorder characterized by the degeneration of neurons, as well as by the 
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in improving cognitive dysfunction and preventing cell death 
in a STZ-induced Alzheimer rat model.
MATERIALS AND METHODS
　　　
Animal model 
Male Sprague-Dawley rats (n=50, weighing 250-330 g) were 
used in this study. Rats were maintained under controlled hy-
gienic conditions with a 12 hr light/dark reverse cycle at a 
constant temperature with free access to food and water. All 
animal experiments were performed in accordance with the 
Korean Food and Drug Administration guidelines. Protocols 
were reviewed and approved by the Institutional Animal 
Care and Use Committee of the Yonsei Laboratory Animal 
Research Center (Permit #: 10-115). 
Drug treatments
For each experiment, rats were given anesthesia [chloral hy-
drate 300 mg/kg, intraperitoneal (i.p)], followed by a single 
injection of STZ (1.5 mg/kg, dissolved in a vehicle consist-
ing of 0.05 M citrate buffer) bilaterally into each lateral ven-
tricle (5 μL/ventricle). Control animals were given an equal 
volume of intracerebroventricular (icv) vehicle via the same 
procedure. Agm was purchased from Sigma (Sigma, St. 
Louis, MO, USA), dissolved in normal saline (pH 7.4), and 
administered to rats via an intra-peritoneal route. Rats were 
injected with Agm (100 mg/kg) daily for up to two weeks 
after surgery. The concentration of Agm (100 mg/kg) was 
determined based upon the results of our previous study.25 
Experimental design 
The sham group (n=15) received bilateral icv injection of 
saline, 5 μL in each rat. The rats in the EC group (n=17) were 
given injection of STZ-icv (1.5 mg/kg, 1st and 3rd days after 
surgery) (Sigma, St. Louis, MO, USA) bilaterally.40 Rats in 
the STZ-Agm group (n=18) were given 5 uL injection of 
STZ-icv (1.5 mg/kg, 1st and 3rd days after surgery) (Sig-
ma, St. Louis, MO, USA) bilaterally and treated with Agm 
[100 mg/kg, intraperitoneal (i.p.) daily for two weeks from 
the 1st day after surgery]. The heads of the rats were posi-
tioned in a stereotactic frame (coordinates of 1.5 mm poste-
rior to the bregma, 1.5 mm lateral to the sagittal suture, 2.5 
mm ventral to the surface of the brain).
Cognition assessment tests
Cognitive evaluation of rats was tested using a Morris wa-
progressive decline of cognitive function. AD exhibits the 
hallmarks of both senile plaques derived from amyloid beta 
(Aβ) and neurofibrillary tangles, especially in the hippocam-
pus or cerebral cortex, relevant to learning and memory.1,2 
When Aβ exists in high concentrations, it forms insoluble 
and fibrillar Aβ plaques, which activate ion channels in the 
cell membrane to induce membrane depolarization and de-
stabilization of intracellular calcium homeostasis.3-5 In partic-
ular, Aβ oligomers cause intracellular Ca2+ overload, leading 
to neuronal death, which can be prevented by N-methyl-D-
aspartate (NMDA) receptor antagonists.6,7
Streptozotocin (STZ) is a glucosamine-nitrosourea com-
pound that, when metabolized, generates a cytotoxic prod-
uct that preferentially destroys pancreatic β cells.8 The alkyl-
ating properties of STZ metabolites generate reactive 
oxygen species and cause oxidative stress.8 Previously, in-
tracerebroventricular streptozotocin (STZ-icv) administra-
tion was shown to induce oxidative stress,9-11 neuronal cell 
damage,12,13 and dysfunctions in learning and memory.8,14,15 
Accordingly, STZ-icv models have been used to assess the 
therapeutic potential of various drugs, as well as other non-
drug therapeutic strategies.16 Additionally, STZ-induced 
learning and memory dysfunction is associated with oxida-
tive stress in animal models.17 Therefore, to attenuate the 
death of neuronal cells caused by a variety of neurodegener-
ative diseases, antioxidants have been spotlighted in poten-
tial treatments of neurodegenerative diseases such as AD.17,18 
Agmatine (Agm) is an endogenous peptide synthesized by 
arginine decarboxylase, and is reported to be present in glia 
and neuronal cells. Several researchers have investigated the 
potential of Agm to improve cognitive function and neuronal 
cell death in various animal models.19-23 Agm, a neurotrans-
mitter or neuromodulator, exerts neuroprotective effects in 
various central nervous system injury models, including neu-
rotrauma and neonatal ischemia animal models. 24-28 Agm, as 
an NMDA receptor antagonist, plays a crucial role in regu-
lating the production of nitric oxide (NO). Since NO can 
enhance a cell’s survival rate under oxidative stress, Agm 
also could protect against damage to cells under oxidative 
stress.29,30 As well, nuclear factor-erythroid 2 related factor 
2 (Nrf2) protects the cell against various stresses and regu-
lates the expression of antioxidant genes, including super-
oxide dismutase, NAD(P)H, and γ-GCS.31-36 Previous stud-
ies demonstrated that Nrf2 is related to cognitive decline.37-39 
Accordingly, this study attempted to investigate whether 
Agm promotes Nrf2 mediated antioxidant signaling. In par-
ticular, we aimed to determine the potential benefits of Agm 
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IRS-1) (1:200, Santa Cruz, CA, USA), 8-oxo-2’-deoxy-
guanosine (8-OHdG) (1:200, Chemicon, Billerica, MA, 
USA), and anti-Aβ (1:200, Millipore, Billerica, MA, USA) 
were applied to the samples for 24 hours at 4°C, followed 
by a 90-minute incubation with appropriate florescence sec-
ondary antibody (1:100, Invitrogen, Carlsbad, CA, USA) 
and three washings in PBS for 10 minutes each. After three 
washes in 0.1% phosphate buffered saline with Tween-20 
(PBST), the sections were incubated with rhodamine-con-
jugated sheep anti-rabbit or sheep anti-mouse secondary 
antibody that was diluted to 1:200 with 5% BSA fraction V 
in 0.1% PBST for 2 h in the dark at room temperature. Af-
ter three washing in PBS, all sections were incubated with 
1 μg/mL of 4’,6-diamidino-2-phenylindole (Sigma-Aldrich, 
Sigma, St. Louis, MO, USA) and 2 μg/mL of propidium io-
dide (Sigma-Aldrich, USA) for a counter staining. Tissues 
were then visualized under a confocal microscope (Zeiss 
LSM 700, Carl Zeiss, Thornwood, NY, USA).
Western blot analysis
For Western blot analysis, rats from all groups were sacri-
ficed and their brains were perfused with saline through the 
heart aorta to rinse away traces of blood. Next, the portion 
of the brain comprising the hippocampus and cortex was 
dissected for extraction of proteins and treated with lysis 
buffer (1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 10 
mM Tris (pH 7.4), 1 mM Ethylene-di-amine tetra acetic 
acid, 1 mM ethylene glycol tetraacetic acid (pH 8.0), 0.2 
mM sodium orthovanadate, 0.2 mM phenyl methyl sulfo-
nyl fluoride, and protease inhibitor cocktail). Isolated pro-
teins were centrifuged at 12000 rpm at 4°C. Equal amounts 
of protein (20 μg) from the supernatants were separated on 
a 10% acrylamide gel and proteins were electrophoretically 
transferred onto nitrocellulose membranes. After blocking 
with 5% skim milk for 2 hrs, the membranes were incubated 
with primary antibodies against Bcl2 (1:1000, Santa Cruz, 
San Jose, CA, USA), Bax (1:1000, Santa Cruz, San Jose, 
CA, USA), cleaved caspase-3 (1:1000, Cell signaling, Bill-
erica, MA, USA), PI3K (1:2000, Millipore, Billerica, MA, 
USA), Nrf2 (1:200, Santa Cruz, San Jose, CA, USA), γ-GCS 
(1:500, Thermo Scientific, Bremen, Germany), and β-actin 
(1:1000, Millipore, Billerica, MA, USA) at 4°C overnight. 
Later the membranes were washed three times for 5 min 
each with TBST. The detection of secondary anti-rabbit and 
anti-mouse antibodies (1:3000, New England Bio labs, 
USA) was conducted for 1 hour at room temperature. After 
washing with PBST (0.05% with Tween 20) three times, 
ter maze.41 Before conducting the Morris water maze test, 
we conducted pre-training. For all trials, a single rat was 
placed in a pool, facing the wall, at a different starting point 
(NW, NE, SW, or SE), and was then allowed to swim for a 
maximum of 60 seconds or until it reached the platform. If 
the rat failed to find the platform during the trial, it was 
manually guided to the platform by the investigator and 
placed on top of it for 15 seconds. Next, an apparatus con-
sisting of a circular pool (200 cm diameter, 60 cm high) 
filled with water (depth 30 cm; 24±1°C) was placed in a 
room with consistently positioned spatial cues. An escape 
platform (15 cm diameter) was placed in the middle of one 
of the quadrants, 1.5 cm below the water surface, equidis-
tant from the sidewall and the middle of the pool. The time 
required to reach the platform (escape latency) was mea-
sured in each trial. After the acquisition stage, a probe test 
was performed after removing the platform. We measured 
the latency up to the point when the rat traversed the loca-
tion where the platform used to be as a measure of memory.
Hematoxylin and eosin (H&E) staining
Rats were anesthetized and perfused as previously men-
tioned.42 Rat brains were cut into coronal slices of 2 mm 
thickness using a rat brain matrix (Ted Pella, Redding, CA, 
USA). Next, the brain slices were fixed with 4% parafor-
maldehyde (pH 7.4) for 3 days and subsequently embedded 
in a paraffin block. The paraffin blocks containing the hip-
pocampus and cortex were deparaffinized and re-hydrated 
with different concentrations of alcohol and xylene. After 
hematoxylin and eosin (H&E) staining, stained hippocam-
pus and cortex sections were examined under a microscope. 
Immunohistochemistry
Five μm thick frozen brain sections were harvested onto 
clean glass slides (Thermo Scientific, Bremen, Germany), 
air-dried, and fixed in cold acetone for 10 minutes at -20°C. 
The slides were washed first in Tris-buffered saline (TBS) 
and then incubated with 0.3% H2O2 in methanol to quench 
endogenous peroxidase activity. Followed by a series of 
washes (three times with distilled water), the sections were 
blocked with 10% normal rabbit serum. Frozen brain sec-
tions (20 μm) were fixed in ice-cold acetone for 20 minutes. 
To block specific staining, sections were incubated in 5% 
bovine serum albumin (BSA) (Sigma-Aldrich, Sigma, St. 
Louis, MO, USA) diluted in PBS for 30 minutes before ad-
dition of primary and secondary antibodies. Primary anti-
bodies for phosphorylated insulin receptor substrate-1 (p-
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Our findings suggest that Agm treatment could improve 
learning and memory dysfunction in STZ-induced Al-
zheimer rats.
Agmatine treatment attenuates histological 
abnormalities in hippocampus and cortex regions of 
STZ-icv rats 
To investigate morphological differences in cells, we con-
ducted H&E staining. The H&E staining of Cornu Ammo-
nis (CA)1, CA2, and CA3 regions of the hippocampus re-
vealed a large number of degenerated cells in the EC group 
compared with STZ-Agm group (Fig. 2A), which were evi-
denced by a decrease in the number of H&E stained cells. 
The EC group exhibited greater shrinkage of the nuclei of 
cells than those in the STZ-Agm group. Fig. 2B shows that 
the number of abnormal cells in the cortical region were 
higher in the EC group than the STZ-Agm group. Fig. 2 in-
dicates that Agm treatment reduces STZ-induced histologi-
cal abnormalities in hippocampus and cortex regions, com-
pared with the EC group. 
Agmatine treatment inhibits the cell death pathway in 
STZ-icv rats 
To confirm apoptotic cell death in the EC group and the 
STZ-Agm group, western blot analysis was conducted to 
check expression of apoptotic proteins. Fig. 3A indicates 
that the presence of cleaved caspase-3, an active form of 
caspase-3, was attenuated in the STZ-Agm group com-
pared with the EC group. Additionally, in the present study, 
the anti-apoptotic effect of Agm was investigated by check-
ing the expression of proteins, such as Bax, Bcl2, and 
PI3K, using western blotting. Among the quantitative west-
ern blot results, the expression of Bax, known as a pro-
apoptotic protein, was higher in the EC group than the 
STZ-Agm group (Fig. 3C). In contrast, Bcl2, known as an 
anti-apoptotic protein, was expressed more in the STZ-
Agm group than the EC group (Fig. 3B). Also, the STZ-
Agm group showed increased expression of PI3K, known 
to be related to survival pathways and insulin signal trans-
duction, compared with the EC group (Fig. 3D). Fig. 3 sug-
gests that Agm treatment inhibits cell death signaling in 
STZ-induced Alzheimer rats.
Agmatine treatment promotes the Nrf2-mediated 
antioxidant pathway in STZ-icv rats 
To detect the generation of Reactive Oxygen Species (ROS), 
which causes DNA damage to the cells, we conducted 
immunoreactive signals were detected by chemilumines-
cence with an ECL detection system (Amersham Life Sci-
ence, London, UK) using the LAS 4000 program.  
Statistical analysis
Statistical analyses were carried out using SPSS 18.0 soft-
ware (IBM Portsmouth, IBM North Harbour, Portsmouth, 
UK). All data are expressed as means±S.E.M. Statistical 
significance in intergroup differences was determined by 
one-way analysis of variance, followed by Scheffe’s post 
hoc multiple comparison test. Each experiment included at 
least three replicates per condition. Differences with a p 
value less than 0.05 were considered statistically signifi-
cant.
 
RESULTS
 
Agmatine treatment attenuates Aβ accumulation and 
improves cognitive dysfunction in STZ-icv rats 
To determine the accumulation of Aβ, on the 21st day fol-
lowing STZ injection, Aβ staining was performed in the 
sham, EC, and STZ-Agm groups. The expression of Aβ 
was considerably decreased in the STZ-Agm group com-
pared to the EC group (Fig. 1A). To confirm phosphoryla-
tion of IRS-1 by Agm treatment in STZ-icv rats, we conduct-
ed immunohistochemistry using phospho-IRS-1 antibody, 
because IRS-1 plays a key role in transmitting signals from 
the insulin receptors to intracellular pathways. In the STZ-
Agm group, both hippocampus (Fig. 1B) and cortex re-
gions (Fig. 1C) showed an increase in IRS-1 phosphoryla-
tion compared to the EC group. These data indicated that 
Agm treatment could promote IRS-1 phosphorylation in 
STZ-icv rat models. 
In previous studies, Morris water maze tests have been 
commonly applied for the assessment of cognition and 
memory functions. To confirm the enhancement of memo-
ry function in our STZ-induced Alzheimer rat model upon 
treatment with Agm, we conducted Morris water maze 
tests. The swimming times of four trials per day for 5 days 
in each group are shown in Fig. 1. Escape latency time (days 
1-5) (to find a hidden platform) was significantly prolonged 
in the EC group compared to the sham group (Fig. 1D). 
Fig. 1D shows that the STZ-Agm group animals presented 
a significantly lower latency to find the platform than the 
EC group. The animals of the STZ-Agm group demonstrat-
ed improved Morris water maze acquisition performance. 
Effect of Agmatine in STZ-Induced Alzheimer Rats 
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DISCUSSION
AD is one of the most prevalent degenerative diseases in the 
elderly. AD is characterized by progressive memory loss and 
cognitive impairment.43 The administration of STZ to the 
central nervous system (CNS) generates similar pathology to 
AD.44-46 Previously, STZ-icv administration was shown to in-
duce oxidative stress, neuronal cell damage, and dysfunction 
in learning and memory.8,14,15 Accordingly, STZ-icv models 
have been used to assess the therapeutic potential of various 
drugs. Hence, we employed a STZ-induced Alzheimer rat 
8-OHdG staining. The immunohistochemical localization 
of 8-OHdG revealed a decreased number of 8-OHdG posi-
tive cells in the STZ-Agm group compared to the EC group 
(Fig. 4A). Fig. 4A indicates that ROS generation is de-
creased in the STZ-Agm group compared with the EC 
group. The western blot data for Nrf2 (known as an antioxi-
dant transcription factor) (Fig. 4B) and γ-GCS (an impor-
tant enzyme in glutathione synthesis) (Fig. 4C) show that 
Agm treatment promotes Nrf2-mediated antioxidant path-
way signaling. Fig. 4 indicates that Agm treatment prevents 
cell death and promotes Nrf2-mediated antioxidant signal-
ing in STZ-induced Alzheimer rats.
Fig. 1. Agmatine attenuated Aβ accumulation and promoted phosphorylation of IRS-1 in the STZ-icv rat model. (A) The expression of Aβ 
accumulation in the sham group, EC group, and STZ-Agm group. The image was shown at the magnification of 400. Scale bar: 200 μM. 
(B) The expression of phosphorylated IRS-1 in the sham, EC, and STZ-Agm groups in hippocampus sections. The image was shown at the 
magnification of 200. Scale bar: 400 μM. (C) The expression of phosphorylated IRS-1 in the sham, EC, and STZ-Agm groups in cortex sec-
tions. The image was shown at the magnification of 200. Scale bar: 400 μM. (D) The latency time of Morris water maze was measured in 
the sham, EC, and STZ-Agm groups. The time required to reach the platform (escape latency) was measured on each day (1-5 days). 
Data were expressed as mean±SEM, and were analyzed statistically using one-way ANOVA, followed by Scheffe’s post hoc (*p<0.05, 
**p<0.001 compared to Sham group, †p<0.05, ††p<0.01 compared to EC group with STZ-Agm group). DAPI, 4’,6-diamidino-2-phenylindole; 
PI, propidium iodide; p-IRS-1, phosphorylated IRS-1; STZ, streptozotocin; EC, experimental control.
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are associated with cognitive function in CNS diseases.56 
Insulin dysregulation contributes to AD pathologies by re-
ducing brain glucose utilization.57-59 Insulin affects neuronal 
cognition and memory by regulating ion channels and neu-
rotransmitter receptors in AD brains.60,61 Considering that 
insulin signal transduction is important for cognitive func-
tion,59,62-64 our data indicated that Agm could induce the ac-
tivation of brain insulin signal transduction and improve 
learning and cognitive decline in STZ-induced Alzheimer 
rat model. 
In addition, Agm inhibits cell death by regulating the pro-
duction of NO,29,30,65 and also attenuates neuronal cell death 
in neurodegenerative animal models.19-23,66-68 During the on-
set of AD, there is increased oxidative stress leading to the 
retardation of cognitive ability.69-71 In the present study, wa-
ter maze test results highlighted significant improvements in 
test scores in the STZ-Agm group, compared with EC group. 
These functional outcomes may because Agm, a NMDA an-
tagonist, improves memory function in EC rats.72,73 Addition-
ally, our H&E staining data indicated that the excessive 
production and accumulation of ROS by Aβ can cause 
functional and structural changes in critical macromole-
cules leading to lipid peroxidation, protein oxidation, and 
model to investigate AD like pathologies. 
In previous studies, the administration of STZ in the CNS 
generated similar pathology to AD, mainly accumulation of 
Aβ.46,47 In regards to the pathologic status of AD, the hyper 
activation of glutamate receptor and continuous Ca2+ influx 
by Aβ results in neuronal damage and cognitive dysfunc-
tion.48-50 Additionally, a previous study showed that meman-
tine, as a glutamate NMDA receptor channel antagonist, 
blocks NMDA overstimulation upon excitoxicity; accord-
ingly, memantine was suggested to be of potential use in 
the treatment of AD.51 Several studies reported the neuro-
protective effects of Agm in a variety of neurodegenerative 
pathologies through possible blockade via NMDA chan-
nels.24,25,30,52-54 As shown in our data, Aβ accumulation in 
damaged brain regions was decreased in the STZ-Agm 
group compared to the EC group. 
Also, STZ-icv in rats can induce brain insulin system 
dysfunction and induce progressive deficits in learning, 
memory, and cognitive behavior like sporadic AD.12,46 As 
shown in our data, STZ inhibits phosphorylation of IRS-1 
in rats. IRS-1 plays a key role in transmitting signals from 
insulin receptors to intracellular pathways.55 Accordingly, 
several studies demonstrated that IRS-1 signaling pathways 
Fig. 2. Histological analysis of the hippocampus and cortex regions in STZ-icv rats. (A) Hippocampus sections from the sham group (a, b, 
c), EC group (d, e, f), and STZ-Agm group (g, h, i). CA1 (a, d, g), CA2 (b, e, h), CA3 (c, f, i). Scale bars were indicated. (B) Cortex sections 
from the sham group (a), EC group (b), and STZ-Agm group (c). All slides were stained by hematoxylin and eosin (H&E). STZ, streptozoto-
cin; EC, experimental control. 
CA1 CA3CA2
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B
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lated in AD models.83 Bax also plays an essential role in 
oligomeric Aβ-induced neuronal cell death.84 In the present 
study, Bax and Bcl285,86 were measured. Agm treatment sig-
nificantly decreased the expression of 8-OHdG, cleaved 
caspase-3, and Bax, and increased the expression of Bcl2 in 
STZ-induced Alzheimer rats. 
PI3K signaling cascade promotes NO generation through 
the activation of endothelial nitric oxide synthase.63,87 In ad-
dition, the PI3K/Akt signaling pathway plays crucial roles 
in cell survival, growth, gene expression, apoptosis, metab-
olism,88 and also, neuronal survival.89 Liu, et al.64 demon-
strated that the insulin-PI3K/Akt signaling pathway is re-
duced in AD brain. As IRS-1 plays a key role in transmitting 
signals from the insulin receptors to intracellular pathways 
including the PI3K pathway, the phosphorylation of IRS-1 
by Agm treatment could improve cognitive decline and 
protect against cell death by activating the PI3K pathway. 
DNA cleavage. Earlier studies have suggested that antioxi-
dant treatment could therapeutically cure and prevent neu-
rodegenerative diseases, especially sporadic AD.17,18 More-
over, previous researchers reported that antioxidants such 
as melatonin, vitamin E, and selegiline can be used to cure 
AD.74-77 
Also, STZ-induced learning and memory dysfunction is 
considerably associated with oxidative stress in animal 
models.78-80 The levels of molecular markers for DNA (par-
ticularly 8-OHdG) are reported to be elevated in the brains 
of patients with AD.72 Bcl2 is neuroprotective against apop-
totic cell death caused by Aβ.81 Accordingly, overexpres-
sion of Bcl2 could attenuate the processing of amyloid pre-
cursor protein and tau and reduce extracellular deposits of 
Aβ.82 Bcl2 protects neuronal cells by inhibiting the activation 
of caspase-3.81,82 Previously, Bcl-2 expression was shown to 
be upregulated, while Bax and caspase-3 were down regu-
Fig. 3. Agmatine treatment decreased the expression of apoptotic proteins in STZ-icv rats. (A) Representative blots showed the protein 
levels of cleaved caspase-3 from the total protein extracts prepared from the hippocampus regions of each group. Bars represented the 
relative protein quantification of active cleaved caspase-3 on the basis of β-actin, respectively. Representative blots showed the protein 
levels of Bcl2 (B) and Bax (C) from the total protein extracts prepared from the hippocampus regions of each group. (D) Representative 
blots showed the protein levels of PI3K from the total protein extracts prepared from the hippocampus regions of each group (*p<0.05, 
**p<0.01 compared to Sham group, †p<0.05, ††p<0.01 compared to EC group). STZ, streptozotocin; EC, experimental control.
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for alleviating neuronal cell apoptosis and cognitive de-
cline in AD.
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Nrf2 plays an important role in regulating cellular oxidative 
stress and controls the expression of many detoxifying genes 
such as catalase, superoxide dismutase, heme oxygenase-1 
(HO-1), NAD(P)H, and γ-GCS.31-34 Nrf2 activation can in-
duce the antioxidant pathway and protect cells against oxi-
dative stress.35,36 In addition, Nrf2 ameliorates cognitive im-
pairment.37-39 Our western blot data for Nrf2 and γ-GCS 
indicated that Agm could promote Nrf2-mediated antioxi-
dant pathways in STZ-induced Alzheimer rats. 
In conclusion, Agm could improve cognitive decline by 
decreasing accumulation of Aβ and ameliorating insulin 
signal transduction. Also, Agm could protect against dam-
age to cells by activating Nrf2-mediated antioxidant sig-
naling. Hence, Agm may be a promising therapeutic agent 
Fig. 4. Agmatine treatment decreased the immunoreactivity of 8-OHdG and increased the expression of Nrf2 and γ-GCS in STZ-icv rats. 
(A) Immunohistochemistry images showed immunostaining of 8-OhdG (red) in the sham group, EC group and STZ-Agm group. The image 
was shown at the magnification of 400. Scale bar: 200 μM. (B) Western blot showed the amount of Nrf2 protein from the total protein ex-
tracts prepared from the hippocampus regions of each group. Bar graph showed the quantification of Nrf2 protein levels in all groups. (C) 
Western blot showed the expression levels of γ-GCS from the total protein extracts prepared from the hippocampus regions of each 
group. Bar graph showed the quantification of γ-GCS protein levels (*p<0.05, **p<0.01 compared to the sham group, †p<0.05 compared to 
the EC group). DAPI, 4’,6-diamidino-2-phenylindole; STZ, streptozotocin; GCS, glutamyl cysteine  synthetase; EC, experimental control.
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